AI Prostate Cancer Test Added to NCCN Guidelines for Post-Surgery Recurrence
Posted on 16 Nov 2026
Following radical prostatectomy, an estimated 20% to 40% of prostate cancer patients develop biochemical recurrence, marked by rising prostate-specific antigen levels that may indicate cancer recurrence. Clinicians must then determine whether to add hormone therapy to salvage radiation, balancing potential treatment benefits against quality-of-life effects. To help guide these decisions, an artificial intelligence-based test included in clinical guidelines provides risk stratification using pathology images and clinical data.
Artera’s ArteraAI Prostate Test (Post-RP) has been included in the updated National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology for Prostate Cancer, Version 1.2027. The test is listed as a risk stratification tool for patients with biochemical recurrence following radical prostatectomy. According to Artera, its AI-based tests are the only such risk stratification tools included in the prostate cancer guidelines and are among just two tests recommended across intermediate-risk, high-risk, and biochemical recurrence patient groups.

The test uses multimodal artificial intelligence to analyze digitized surgical pathology images alongside clinical data, without requiring additional tissue. By assessing the risk of disease progression, it aims to help clinicians make more informed treatment decisions for patients considering salvage therapy after radical prostatectomy.
Commercially available since December 2025, ArteraAI Prostate Test (Post-RP) is supported by validation data published in European Urology and first presented at the 2024 American Urological Association Annual Meeting. The findings demonstrated its ability to stratify patients by metastasis risk and identify those more likely to benefit from adding hormone therapy to salvage radiation. The test has also undergone external validation in institutional cohorts from the University of California, San Francisco, and Mayo Clinic.
Artera’s broader diagnostic portfolio includes FDA-authorized software products ArteraAI Prostate, which received De Novo authorization, and ArteraAI Breast, which obtained 510(k) clearance. The company also holds CE marking for its prostate and breast cancer in vitro diagnostic tests and operates a clinical laboratory in Jacksonville, Florida.
“Artera’s technology supports treatment decisions at multiple points in prostate cancer care. The addition of our test within the NCCN Guidelines for use in the post-RP salvage setting reinforces the role of AI-powered insights in helping clinicians make more personalized, evidence-based treatment decisions throughout a patient’s cancer journey,” said Andre Esteva, CEO and co-founder of Artera.
Related Links
Artera







.jpg)